$15.4+ Billion Coronary Stents Market by 2030 Amid Rising Cardiovascular Disease Burden and Technological Advancements

Fueled by Improved Patient Outcomes, Drug-Eluting Innovations, and Expansion Across Asia-Pacific, the Market Surges at 6% CAGR

PORTLAND, OR, UNITED STATES, July 18, 2025 /EINPresswire.com/ -- The global Coronary Stents Market is experiencing significant momentum and is poised to reach $15.4 billion by 2030, growing at a compound annual growth rate (CAGR) of 6% from 2021. This impressive growth is fueled by a surge in coronary artery disease (CAD) cases, continuous technological advancements in stent-based interventions, and expanding access to cardiovascular care in emerging markets.

Coronary stents, vital life-saving devices used in percutaneous coronary interventions (PCI), are placed into the arteries to keep them open following narrowing or blockage due to atherosclerosis. With over 90% of PCI procedures now involving stent implantation, these devices are vital in preventing acute cardiac events, reducing angina, and improving long-term survival.

“Cardiovascular disease remains the world’s leading cause of death. The global uptick in sedentary lifestyles, hypertension, and diabetes has only accelerated demand for minimally invasive solutions like coronary stenting,” said Dr. Amara Desai, Interventional Cardiologist and Clinical Researcher. “Stent innovation, coupled with increasing insurance penetration in developing countries, is setting the stage for unprecedented market expansion.”

Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/2187

Key Market Drivers
Rising global incidence of coronary artery disease: Increasing geriatric population and lifestyle-related risk factors are heightening demand for effective interventions.

Technological Innovations: Advancements such as biodegradable and drug-eluting stents are reducing the risks of restenosis and improving patient recovery times.

Wider PCI adoption: Stenting procedures have become the gold standard therapy due to their proven efficacy in critical scenarios such as acute myocardial infarction.

Improved reimbursement and healthcare infrastructure: Wider insurance coverage and government-sponsored initiatives across developing regions are facilitating patient access to stent-based procedures.

Market Segmentation Highlights
By Product Type
Drug-Eluting Stents (DES) led the global market in 2020 and are expected to maintain dominance throughout the forecast period. Their ability to minimize restenosis through localized drug delivery has made DES the preferred choice among cardiologists globally.

Bioabsorbable Vascular Stents are also gaining traction, offering next-gen innovation that naturally dissolve post-therapy, aligning with long-term patient safety goals.

By Biomaterial
Metallic Biomaterials secured the largest market share due to their durability, cost-efficiency, and widespread clinical efficacy in vascular healing.

Polymeric and Natural Materials, while emerging, are expected to carve out future market share, especially with new-generation bioresorbable device technologies.

By End User
Hospitals were the primary drivers for market revenue in 2020, thanks to increasing interventional cardiology capacities, favorable reimbursement policies, and expanding healthcare infrastructure.

Regional Insights
Asia-Pacific Positioned as Fastest-Growing Region
The Asia-Pacific region is experiencing a major uptick in coronary stent adoption. This is fueled by:

A rise in geriatric population, projected to reach 1.3 billion by 2050.

A growing number of cardiac care centers and specialized hospitals.

Intensifying public and private healthcare investments, especially in China, India, South Korea, and Southeast Asia.

Increasing procedure volumes as awareness of cardiovascular risk factors and available interventions grows across urban and rural populations.

North America and Europe remain key mature markets due to early adoption of advanced stent technologies and highly regulated, well-funded healthcare systems.
Future Outlook: Innovation, Access, and Affordability
While coronary stents continue to improve survival and reduce adverse cardiac events, market challenges remain. High procedural costs and the availability of alternative treatments such as coronary artery bypass grafting (CABG) can restrain growth in budget-sensitive markets.

However, rising reimbursements, R&D advances, and the introduction of newer, safer stent platforms are expected to offset these barriers and unlock widespread adoption. Stakeholders are also focusing on next-gen stents, including smart and drug-coated biodegradable platforms, expected to revolutionize interventional cardiology by 2030.

Leading Market Players
Some of the global leaders defining the competitive landscape of the coronary stents industry include:

Abbott Laboratories

Boston Scientific Corporation

Medtronic plc

B. Braun Melsungen AG

Biotronik SE & Co. KG

Becton Dickinson and Company

MicroPort Scientific Corporation

Terumo Corporation

Biosensors International Group, Ltd.

Elixir Medical Corporation

Enquire Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/2187

Sachin Bhandare
Allied Analytics LLP
+91 81490 46454
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.